CCM
BIO icon

Chilton Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Chilton Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2
Closed -$692 – 616
2024
Q1 		$692 Hold
2
– – ﹤0.01% 578
2023
Q4 		$646 Buy
+2
New +$627 ﹤0.01% 581
2022
Q3 		– Sell
-19
Closed -$9K – 252
2022
Q2 		$9K Buy
+19
New +$9.89K ﹤0.01% 475
2022
Q1 		– Sell
-19
Closed -$14K – 261
2021
Q4 		$14K Buy
+19
New +$14.2K ﹤0.01% 453

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Chilton Capital Management's BIO Position: Q2 2024 in Review

Chilton Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 2 shares — an estimated $692 sold.

Chilton Capital Management first reported a position in BIO in Q4 2021 and held it in 4 quarters. The position peaked at $14K in Q4 2021. 440 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

  • Chilton Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
  • Chilton Capital Management sold 2 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $692.
  • Chilton Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and held it in 4 quarters.
  • Chilton Capital Management's Bio-Rad Laboratories Class A position peaked at $14K in Q4 2021.
  • 440 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Chilton Capital Management's 13F filing for Q2 2024, filed 1 Aug 2024.